iMetabolic Biopharma Corporation is engaged in drug discovery using a tech-powered approach to improve traditional biotechnology methods. It focuses on making drugs more effective and affordable.

iMetabolic Biopharma Corporation

DVLP is building a new infrastructure for drug development by digitizing drug assets, financing, and development workflows to accelerate the process of turning molecules into medicines.

DVLP

iMetabolic Biopharma Corporation | 380 followers on LinkedIn. Improving Health Through Innovation | iMetabolic Biopharma Corporation (iMBP) is an exciting early stage platform biopharma company that is developing First In Class therapeutics for the treatment of a number of diseases with high unmet medical need. Through the application of its proprietary iPlatform technology, iMBP has established itself as a Leader in TechBio, a nouveau field of drug discovery and development driven by technology innovation. Having already established a pipeline of five early stage therapeutic assets, with additional molecules already in design phase, iMBP is at the precipice in its next leg of evolution.

Nathan Hyland

Business Development | Corporate Development | Product Development | Vendor Management

Ryan Haverstock

PhD Biochemist | Protein Engineering and Structural Biology Expert | Fluorescence Assay Developer | Passionate About Biotechnology Innovation

Patrick Kelly, PhD

Marty Emanuele

We were featured in VentureBeat . Great job iMBP team.

Check out our CEO as he shares the stage some Health and Wellness industry superstars. We are at a critical inflection point and Urban A. Kiernan, Ph.D. lays it out there!

We are thrilled to announce that iMBP has received its second NIH grant, a significant milestone in our journey. Recently, our Founder and CEO shared insights on the DNA of Things Podcast, discussing the evolution of iMBP and its impact on the scientific community. Listen to the full episode to learn more. #iMBPSuccess #NIHGrant #ResearchInnovation #Podcast #LifeScience

iMetabolic Biopharma (iMBP) just got featured on Venture Capital Post for being a leader in the TechBio industry! The article outlines exactly what differentiates us as TechBio from the traditional biopharma players in dealing with: - Excessive drug discovery cost, - Less than desirable therapeutic performance and - Extreme timelines in getting drugs to market. We are so excited about the direction our company is growing and know that there is so much more to come. Thank you to every iMBP community member who have made it possible for us to get to this point. We are excited to be on this journey with you! 🙏 🙏 If you want to read the full article, see the post below 👇 Thank you VCPost Inc. for picking up the iMBP story

This is our Founder and CEO, Urban A. Kiernan, Ph.D. . Register today for this mind blowing event🤯…IGNITE by Coach360 🔥🔥🔥. Nexgen MD 360 Bob Thomas Eloiza Tecson Nathan Hyland Kathleen Ferguson

As we approach the fiscal year-end, it's crucial to stay updated on new grant funding opportunities. Also, the recent Decoding Health Podcast episode featuring Dr. Malú Gamez Tansey sheds light on Alzheimer’s Disease and gut health's impact on disease development. Stay informed. #FiscalYearEnd #GrantFunding #Healthcare #Research #AlzheimersDisease

This is a great opportunity for Urban A. Kiernan, Ph.D. to showcase his knowledge base and engage with experts to break down the black box of science. Have a watch: https://lnkd.in/grh6zeaW

Small business supporting small business is how progress gets done. Congratulations to Dr. Micah Olson and Valley Healthspan on the launch!

Exciting news! This summer, the Decoding Health Podcast by Dr. Urban A. Kiernan will be launching. Stay informed on health and science topics with weekly episodes and shorts covering GLP-1 RA, Alzheimer’s Disease, AI in drug development, and more. Join the iMBP community and learn from leading experts in the field. Link in bio. Don't miss this opportunity! #DecodingHealth #HealthPodcast #HealthScience #iMBPCommunity #SciencePodcast

Brilliance in thought right here. Don’t take market share…create the market. To me and iMetabolic Biopharma Corporation , that is the whole point of innovation. #innovation #imbp #therapeutics #biotech #techbio

Metric
Company Name	iMetabolic Biopharma Corporation	DVLP
Symbol
MSH ID	COM:IMBIOPHARMA	COM:DVLPMEDICINES
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals
Country	US	US
Stage
Employee Count
Website	imbiopharma.com	dvlpmedicines.com
LinkedIn	imetabolic-biopharma-corporation	dvlpmedicines
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		133
Web Traffic Growth		-0.55
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

IMBI

COM:IMBIOPHARMA

iMetabolic Biopharma Corporation

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue